Vertex Pharmaceuticals (VRTX) Deferred Taxes (2011 - 2026)

Vertex Pharmaceuticals' Deferred Taxes history runs 16 years deep, the most recent figure standing at -$65.3 million for Q1 2026.

• In Q1 2026, Deferred Taxes rose 65.92% year-over-year to -$65.3 million; the TTM figure through Mar 2026 stood at -$384.5 million (down 0.63% YoY), while the FY2025 annual figure was -$510.8 million, down 46.44% from the prior year.
• Deferred Taxes for Q1 2026 stood at -$65.3 million, down from $30.5 million in the prior quarter.
• The five-year high for Deferred Taxes was $148.1 million in Q4 2022, with the low at -$235.9 million in Q3 2025.
• The 5-year median for Deferred Taxes is -$118.8 million (2024), against an average of -$102.2 million.
• The sharpest annual moves came in 2022 and 2023: Deferred Taxes soared 453.46% in 2022, then plunged 821.95% in 2023.
• Vertex Pharmaceuticals' Deferred Taxes stood at $148.1 million in 2022, then tumbled by 188.45% to -$131.0 million in 2023, then soared by 139.39% to $51.6 million in 2024, then sank by 40.89% to $30.5 million in 2025, then sank by 314.1% to -$65.3 million in 2026.
• Business Quant data shows VRTX's Deferred Taxes at -$65.3 million in Q1 2026, $30.5 million in Q4 2025, and -$235.9 million in Q3 2025.